Cost & Management of Oncology Combination RegimensOverview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there Share XCost & Management of Oncology Combination Regimenshttps://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/
Innovative contracting in Europe – a Trojan horse?Overview With pricing of drugs at the centre of political and social debate, the market access and pricing Share XInnovative contracting in Europe – a Trojan horse?https://pharmaphorum.com/market-access-2/innovative-contracting-in-europe-a-trojan-horse/
How pharma marketing can stay ahead of the evolving customer journeyOverview View our webinar which took place on Tuesday 23rd July at 16:00 BST / 11:00 EST / Share XHow pharma marketing can stay ahead of the evolving customer journeyhttps://pharmaphorum.com/digital/how-pharma-marketing-can-stay-ahead-of-the-evolving-customer-journey/
Launch excellence in a disrupted world – challenges & opportunitiesOverview The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care Share XLaunch excellence in a disrupted world – challenges & opportunitieshttps://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/
Orphan medicines launch excellence: sustaining launch successOverview Launching orphan medicines excellently will become even more important over the next five years as more patients Share XOrphan medicines launch excellence: sustaining launch successhttps://pharmaphorum.com/market-access-2/orphan-medicines-launch-excellence-sustaining-launch-success/
Navigating new frontiers: Ways to find space in the future RA marketOverview Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 Share XNavigating new frontiers: Ways to find space in the future RA markethttps://pharmaphorum.com/r-d/navigating-new-frontiers-ways-to-find-space-in-the-future-ra-market/
The 2nd Life Sciences Sector Deal and the NHS 10 Year PlanOverview Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK Share XThe 2nd Life Sciences Sector Deal and the NHS 10 Year Planhttps://pharmaphorum.com/market-access-2/the-2nd-life-sciences-sector-deal-and-the-nhs-10-year-plan/
Cancer, genomics and personalised medicine: Modelling oncology’s futureOverview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in Share XCancer, genomics and personalised medicine: Modelling oncology’s futurehttps://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/
Metrics to meaning: demonstrating the value of medical communicationsOverview Medical affairs and publications teams are under increasing pressure to demonstrate effectively the success of the medical Share XMetrics to meaning: demonstrating the value of medical communicationshttps://pharmaphorum.com/sales-marketing/metrics-to-meaning-demonstrating-the-value-of-medical-communications/
